| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d4ac6af8b48f0434253504511eb5f89 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2016-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd8ed103d269f3cabe2ed7b290664ac3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10f02aac258a5b2f0ab92b433067fddc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7538b0f78e005dc95daf4fd4c9060290
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6db4d0b111792ff7bd658f6d76010fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ef6a2e3c4f497b49dfe90f3eedcd1d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6585f77899acb8c5ec62dab67f4208f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c812d522053ca53cc33d29fcf1ad740f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2fb22dd03003f614ca627e6f71ddfcf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5013633f58521fe342203c9d8a39b26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e213f4d3261c20f0d87b551d501bc406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d11957a8139900db387e72ee24791e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98e9ffb5419bab9d80cc22d988d2d2be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_559b2f0e81f91f0d1c0ca3ff3bf61cf4 |
| publicationDate |
2018-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3398950-A1 |
| titleOfInvention |
Novel kinase inhibitor against wild-type egfr and mutated egfr |
| abstract |
The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation. |
| priorityDate |
2015-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |